Warfarin Therapy Aaqid Akram MBChB (2013) Clinical Education Fellow.

Slides:



Advertisements
Similar presentations
The management of adverse drug reactions I Ralph Edwards
Advertisements

New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Atrial Fibrillation Service
Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.
Atrial fibrillation Cardiology #2 Gimadeeva A.D..
What a Bloody Mess! A/Professor Kent Robinson Senior Staff Specialist, Liverpool & Campbelltown Hospitals.
Newer Anticoagulants Drug Class Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services October 16, 2013.
Audit of warfarin reversal in over-anticoagulated patients D Wright and J Seal Department of Haematology Pontefract General Infirmary Nov 2002.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
CLINICAL CASES.
DR DIPTI CHITNAVIS HAEMATOLOGY CONSULTANT WEST SUFFOLK HOSPITAL JANUARY 2014 Update on the new oral anticoagulants; 12 months on.
Preventing Anticoagulation Errors with Clinical Dashboards Dan Johnson, Pharm.D., BCPS August 3, 2011.
Chapter Eight Venous Disease Coalition Safe Use of Oral Anticoagulants VTE Toolkit.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
AF and NOACs An UPDATE JULY 2014
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Venous thromboembolism: how long to treat?
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
BLOOD PHARMACOLOGY Peer Support Case 1 Mrs A recently seen one of your colleagues complaining of fatigue. Her blood test results are now back and.
Margaret Jin, BScPHM, PharmD, CGP November Learning Objectives To review the mechanism of action, indications, contraindications, adverse reactions,
New oral anticoagulants: an update
WARFARIN AN OVERVIEW.
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Mark Bleackley MEDG 505 March.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.
Atrial Fibrillation and Anticoagulation
INR for warfarin monitoring ©bpac nz, October 2006.
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
Adam M. Levine, DO, FACC Clinical Assistant Professor of Medicine Rowan University September 12 th, 2015.
Dodson Thompson, DO Northlakes Community Clinic Minong, WI.
ANTI-COAGULATION. ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery ….
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
By the end of this session you should:
Anticoagulation ACCP guidelines 2012
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
ANTI-COAGULATION. ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery ….
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Anticoagulation Update
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Warfarin PSD/HOF001/GB/DC/Rev013 Issued : Review interval:12 months This document may be reviewed and reissued electronically without notice.
Non-vitamin K antagonist oral anticoagulants (NOACs)
Simon Howard Medical Management of Acute Stroke. Fast Recognition of Stroke With sudden onset neurological symptoms: 'FAST' should be used to screen for.
Pharmacokinetics: Warfarin
Net clinical benefit of OAC
ANTICOAGULATION The objectives of this section are: To be able to write prescriptions according to local anticoagulation guidelines To know how to prescribe.
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
Anticoagulants How much, which one & how long?
Anticoagulation: The Latest on Blood Thinners from Aspirin to Xarelto
Understanding Atrial Fibrillation and Stroke Risk
You can never be too Thin…. An Update on NOACs
Warfarin Toxicity Treatment & Management
Anticoagulants in the Treatment of Venous Thromboembolism
Pharmacokinetics: Warfarin
Ortho Warfarin Dosing Protocol
Anticoagulation in Atrial Fibrillation
The normal haemostasis process involves three stages: 1
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Anticoagulation Prepared by Cherie Gan.
Aug, 2016.
Novel oral anticoagulants in comparison with warfarin
Atrial fibrillation (AF) and flutter
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Selecting NOACs for High-Risk Patients
Anticoagulant Reversal
Periprocedural Management of Patients on Anticoagulation
ONLY oral unit-dose warfarin, prefilled Fragmin syringes, and premixed heparin drips are used at CHSB.
How I treat cancer-associated venous thromboembolism
ADAS Anticoagulant Dosing and Advisory Service
Presentation transcript:

Warfarin Therapy Aaqid Akram MBChB (2013) Clinical Education Fellow

Objectives Indications for warfarin therapy Counselling Patients How to commence warfarin therapy How to adjust warfarin doses Common warfarin interactions Warfarin therapy reversal Novell Oral Anticoagulation Drugs (NOADs)

Mechanism of Action + Indications Blocks reduction of vitamin K oxidase to vitamin K IndicationTarget Range (INR)Duration DVT Treatment months PE Treatment2-36 months Atrial Fibrillation2-3Until resolved / lifelong Valvular Heart Disease2-3Until resolved / lifelong Tissue Heart Valves2-3Until resolved / lifelong TIA / Stroke2-3Until resolved / lifelong Recurrent DVT / PE2-3 / 3-4lifelong Intravascular stent2-3Until resolved / lifelong Mechanical prosthetic valves – dependent on brand and cardiologist

Counselling Patients Drug (Yellow Book) (name / colours / side effects) Reason Goal (End point / therapeutic range / length) Missed dose Suboptimal therapy symptoms Over – bleeding from sites Under – thromboembolism Interactions Illness / Surgery Check understanding Where to find more information StrengthColour 0.5 mgWhite 1 mgBrown 3 mgBlue 5 mgPink

Interactions Alcohol Allopurinol Amiodarone Aspirin Steroids Cranberry/grapefruit Juice Garlic Omeprazole Papaya Thyroxine Ciprofloxacin Clarithromycin / Erythromycin Fluconazole / Metronidazole Penicillins Phenytoin Azathioprine Bariturates Carbamazepine CoEnzyme Q10 Oral Contraceptive St John's Wort Vitamin K

Commencing Warfarin Urgent Therapeutic LMWH until within INR range for three consecutive days Rapid Induction – 10mg first 3 days High Risk – 5mg first 3 days >60 years old Liver disease Interacting medication Poor nutritional status Recent surgery Congestive heart failure High risk of bleeding Slow Loading – 2mg for first week

INR Testing 3 days – 12 weeks 1.Has the patient experienced any signs of bleeding or bruising? 2.Is the patient planning any dental or other surgery? 3.Has the patient followed their advised dosage instructions? 4.Has there been a change in the patient’s other medications or dietary habits since their last test? No more than 20% of weekly dose increase (ideally 10%) Computerised Decision Support Software (CDSS)

High INR Bleeding Major – ABCDE / Urgent Haematology: Stop Warfarin 10mg vit K IV Octaplex Minor: Stop Warfarin 2mg vit K Oral / 1mg vit K IV No Bleeding <5 – Reduce warfarin dose >5 – Stop Warfarin >8 – Same as minor bleeding

New oral anticoagulation drugs (NOADs) Rivaroxaban / Apixaban / Dabigatran No regular INR testing required Single dose preparation OD/BD Rapid onset and offset of action Fewer drug/diet interactions Stroke risk / Therapeutic VTE / VTE prophylaxis

MOARenal ExcretionLiver MetabolismReversal DabigatranThrombin Inhibitor80%No Charcoal, Haemodialysis, PCC, Desmopressin, Antifibrolytics RivaroxabanFactor Xa Inhibitor35%Yes PCC, Desmopressin, Antifibrinolytics ApixabanFactor Xa Inhibitor25%Yes PCC, Desmopressin, Antifibrinolytics

OSCE Time Counselling stations

67 year old female New onset AF (now 3 months old) – echo has shown mitral stenosis No previous thromboembolic episodes No renal/liver disease Lots of travelling due to husband’s work Mother died of stroke Provide the Patient with relevant further management options

65 year old male PE 2 weeks ago No previous PE / DVT No liver disease Chronic kidney disease Started on warfarin therapy Unhappy at the number of blood tests required Has Googled about rivaroxaban and wants to be started on it Assess the Patient’s queries and provide further information as required

Any Questions? Thank you

Objectives were: Indications for warfarin therapy Counselling Patients How to commence warfarin therapy How to adjust warfarin doses Common warfarin interactions Warfarin therapy reversal Novell Oral Anticoagulation Drugs (NOADs)